Daniel L. Simmons
Daniel L. Simmons is a professor of chemistry and former director of the Cancer Research Center at Brigham Young University (BYU). He was the discoverer of the COX-2 enzyme that is the target of celecoxib (Celebrex) and other COX-2 inhibitors. He and BYU felt that Pfizer had not properly credited or paid them for Simmons work in this development and brought a suit against Pfizer.
In 2014, the Cancer Research Center was renamed The Simmons Center for Cancer Research in his honor after he stepped down as director after 17 years.
Simmons has bachelors and masters degrees from BYU. He earned his Ph.D. from the University of Wisconsin in 1986. From 1986-1989 he held a post-doctoral Fellowship at Harvard University.
Simmons discovered the COX-2[1] and COX-3 enzymes.
References
- ↑ Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL (April 1991). "Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing". Proceedings of the National Academy of Sciences of the United States of America 88 (7): 2692–6. doi:10.1073/pnas.88.7.2692. PMC 51304. PMID 1849272.
Sources
- Thomson, Linda (October 28, 2009). "Judge orders Pfizer to pay BYU $852K for suit delays". Deseret News.
- BYU Chemistry Department bio of Simmons
- Zoom business info collection of articles on Simmons
- Utah Science medals awards including a short bio of Simmons